loadpatents
name:-0.046660900115967
name:-0.040147066116333
name:-0.0138840675354
Adibhatla; Kali Satya Bhujanga Rao Patent Filings

Adibhatla; Kali Satya Bhujanga Rao

Patent Applications and Registrations

Patent applications and USPTO patent grants for Adibhatla; Kali Satya Bhujanga Rao.The latest application filed is for "process for the preparation of pomalidomide and its purification".

Company Profile
7.36.40
  • Adibhatla; Kali Satya Bhujanga Rao - Hyderabad IN
  • Adibhatla; Kali Satya Bhujanga Rao - Banjara Hills Hyderabad
  • - Hyderabad IN
  • Adibhatla Kali Satya; Bhujanga rao - Andhra Pradesh IN
  • Adibhatla Kali Satya; Bhujanga rao - Hyderbad IN
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Process for the preparation of pomalidomide and its purification
Grant 11,111,228 - Konakanchi , et al. September 7, 2
2021-09-07
Modified process for the preparation of Ceritinib and amorphous form of Ceritinib
Grant 10,604,505 - Konakanchi , et al.
2020-03-31
Pharmaceutical compositions comprising phenylaminopyrimidine derivative
Grant 10,383,872 - Parvataneni , et al. A
2019-08-20
Process For The Preparation Of Pomalidomide And Its Purification
App 20190233389 - Konakanchi; Durga Prasad ;   et al.
2019-08-01
Pharmaceutical compositions comprising phenylaminopyrimidine derivative
Grant 10350209 -
2019-07-16
6,7-dialkoxy Quinazoline Derivatives And Methods Of Treating Drug Resistant And Other Tumors
App 20190201408 - ADIBHATLA KALI SATYA; Bhujanga rao ;   et al.
2019-07-04
Pharmaceutical Compositions Comprising Phenylaminopyrimidine Derivative
App 20190015412 - PARVATANENI; Durga Maheswari ;   et al.
2019-01-17
7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs
Grant 10,106,554 - Konakanchi , et al. October 23, 2
2018-10-23
1H-1,8-naphthyridin-2-ones as anti proliferative compounds
Grant 10,047,088 - Kompella , et al. August 14, 2
2018-08-14
Anhydrous lenalidomide form-I
Grant 10,040,778 - Konakanchi , et al. August 7, 2
2018-08-07
1h-1,8-naphthyridin-2-ones As Anti Proliferative Compounds
App 20170349588 - KOMPELLA; Amala ;   et al.
2017-12-07
7-(morpholinyl)-2-(n-piperazinyl) Methyl Thieno [2, 3-c] Pyridine Derivatives As Anticancer Drugs
App 20170320891 - KONAKANCHI; Durga Prasad ;   et al.
2017-11-09
1H-1,8-naphthyridin-2ones as anti proliferative compounds
Grant 9,765,072 - Kompella , et al. September 19, 2
2017-09-19
Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
Grant 9,750,700 - Adibhatla , et al. September 5, 2
2017-09-05
1h-1,8-naphthyridin-2ones As Anti Proliferative Compounds
App 20170114057 - KOMPELLA; Amala ;   et al.
2017-04-27
6,7-dialkoxy Quinazoline Derivatives And Methods Of Treating Drug Resistant And Other Tumors
App 20170079983 - ADIBHATLA KALI SATYA; Bhujanga rao ;   et al.
2017-03-23
6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors
Grant 9,481,655 - Adibhatla Kali Satya , et al. November 1, 2
2016-11-01
Fermentation process for the production of rapamycin
Grant 9,365,880 - Polavarapu , et al. June 14, 2
2016-06-14
Anhydrous Lenalidomide Form-i
App 20150353525 - Konakanchi; Durga Prasad ;   et al.
2015-12-10
Anhydrous lenalidomide form-I
Grant 9,108,945 - Konakanchi , et al. August 18, 2
2015-08-18
6,7-dialkoxy Quinazoline Derivatives And Methods Of Treating Drug Resistant And Other Tumors
App 20150141421 - ADIBHATLA KALI SATYA; Bhujanga rao ;   et al.
2015-05-21
Process for the preparation glatiramer acetate (copolymer-1)
Grant 8,993,722 - Kota , et al. March 31, 2
2015-03-31
Fermentation Process For The Production Of Rapamycin
App 20150079642 - Polavarapu; Baby Rani ;   et al.
2015-03-19
6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors
Grant 8,921,362 - Adibhatla Kali Satya , et al. December 30, 2
2014-12-30
Anhydrous lenalidomide form-I
Grant 8,877,932 - Konakanchi , et al. November 4, 2
2014-11-04
Polymorphs of erlotinib hydrochloride and method of preparation
Grant 8,748,602 - Jyothi Prasad , et al. June 10, 2
2014-06-10
Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]- -benzamide
Grant 8,735,415 - Kompella , et al. May 27, 2
2014-05-27
Anhydrous Lenalidomide Form-i
App 20140121245 - Konakanchi; Durga Prasad ;   et al.
2014-05-01
Process for the preparation of lapatinib and it's pharmaceutically acceptable salts
Grant 8,664,389 - Jyothi Prasad , et al. March 4, 2
2014-03-04
Process For The Preparation Of Bosentan Monohydrate
App 20130245259 - Kompella; Amala Kishan ;   et al.
2013-09-19
Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
Grant 8,501,962 - Konduri , et al. August 6, 2
2013-08-06
Process To Prepare S-2-hydroxy-3-methoxy-3,3-diphenyl Propionic Acid
App 20130184490 - Kompella; Amala ;   et al.
2013-07-18
Process To Prepare Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate
App 20130172571 - Kompella; Amala ;   et al.
2013-07-04
Polymorphic forms of Sunitinib base
Grant 8,466,190 - Konduri , et al. June 18, 2
2013-06-18
Novel Polymorphs Of Erlotinib Hydrochloride And Method Of Preparation
App 20130131341 - JYOTHI PRASAD; Ramanadham ;   et al.
2013-05-23
Anhydrous Lenalidomide Form-i
App 20130059889 - Konakanchi; Durga Prasad ;   et al.
2013-03-07
Process For The Preparation Of Highly Pure Crystalline Imatinib Base
App 20130060030 - Kompella; Amalia ;   et al.
2013-03-07
Polymorphs of erlotinib hydrochloride and method of preparation
Grant 8,349,855 - Jyothi Prasad , et al. January 8, 2
2013-01-08
Imatinib Mesylate Oral Pharmaceutical Composition And Process For Preparation Thereof
App 20120329810 - Adibhatla; Kali Satya Bhujanga Rao ;   et al.
2012-12-27
Process For The Preparation Of Lapatinib And Its Pharmaceutically Acceptable Salts
App 20120245351 - Jyothi Prasad; Ramanadham ;   et al.
2012-09-27
Novel 4-(tetrazol-5-yl)-quinazoline Derivatives As Anti Cancer Agent
App 20120172380 - Konakanchi; Durga prasad ;   et al.
2012-07-05
Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
Grant 8,183,253 - Kompella , et al. May 22, 2
2012-05-22
Acid Addition Salts Of (3,5-bis Trifluoromethyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]- -benzamide
App 20120077833 - KOMPELLA; Amala Kishan ;   et al.
2012-03-29
6-7,dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
Grant 8,143,250 - Jyothi Prasad , et al. March 27, 2
2012-03-27
4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
Grant 8,080,558 - Konakanchi , et al. December 20, 2
2011-12-20
Crystal form of phenylamino pyrimidine derivatives
Grant 8,067,422 - Kompella , et al. November 29, 2
2011-11-29
Polymorphic form of imatinib mesylate and a process for its preparation
Grant 8,048,883 - Amala , et al. November 1, 2
2011-11-01
Novel Process For The Preparation Of Lapatinib And Its Pharmaceutically Acceptable Salts
App 20110263852 - Jyothi Prasad; Ramanadham ;   et al.
2011-10-27
Acid Addition Salts Of (3,5-bis Trifluoromethyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]- -benzamide
App 20110190328 - Kompella; Amala Kishan ;   et al.
2011-08-04
Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylami- no)-phenyl]-benzamide
Grant 7,939,541 - Kompella , et al. May 10, 2
2011-05-10
Novel Polymorphic Forms Of Sunitinib Base
App 20110105580 - Konduri; Srinivasa Krishna Murthy ;   et al.
2011-05-05
Process For The Preparation Of High Purity Sunitinib And Its Pharmaceutically Acceptable Salt
App 20110092717 - Konduri; Srinivasa Krishna Murthy ;   et al.
2011-04-21
Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
Grant 7,910,598 - Kompella , et al. March 22, 2
2011-03-22
6,7-dialkoxy Quinazoline Derivatives And Methods Of Treating Drug Resistant And Other Tumors
App 20110034459 - ADIBHATLA KALI SATYA; Bhujanga rao ;   et al.
2011-02-10
Methods Of Treating Drug Resistant And Other Tumors By Administering 6,7-dialkoxy Quinazoline Derivatives
App 20110028473 - ADIBHATLA KALI SATYA; Bhujanga rao ;   et al.
2011-02-03
Novel 4-(tetrazol-5-yl)-quinazoline Derivatives As Anti Cancer Agent
App 20100261740 - Konkanchi; Durga Prasad ;   et al.
2010-10-14
Novel Polymorphs Of Erlotinib Hydrochloride And Method Of Preparation
App 20100261738 - Jyothi Prasad; Ramanadham ;   et al.
2010-10-14
Crystal Form Of Phenylamino Pyrimidine Derivatives
App 20090227611 - Kompella; Amala kishan ;   et al.
2009-09-10
Phenylaminopyrimidine Derivatives As Inhibitors Of Bcr-abl Kinase
App 20080306100 - KOMPELLA; Amala Kishan ;   et al.
2008-12-11
Novel Polymorphic Form Of Imatinib Mesylate And A Process For Its Preparation
App 20080255138 - Amala; Kompella ;   et al.
2008-10-16
Intermediates And A Process Employing The Intermediates For The Preparation Of (3-trifluoromethylsulfonyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylami- No)-phenyl]-benzamide
App 20080249121 - Kompella; Amala Kishan ;   et al.
2008-10-09
Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
App 20070232633 - Kompella; Amala kishan ;   et al.
2007-10-04

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed